Bert Bammens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bert Bammens has a total of 267 co-authors. Here are the top co-authors by number of shared publications:
- Dirk Kuypers
Nephrology and Renal Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
46 shared publications - Björn Meijers
Department of Internal Medicine, Nephrology Unit, UZ Leuven, Leuven
44 shared publications Pieter Evenepoel
Department of Microbiology and Immunology, Division of Nephrology, University Hospitals Leuven, Leuven, Belgium
35 shared publicationsYves Vanrenterghem
1] Department of Nephrology, Dialysis and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium [2] Laboratory of Nephrology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium
35 shared publications- Pieter Evenepoel
Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, Katholieke Universiteit Leuven , Leuven
33 shared publications Kathleen Claes
KU Leuven, Department of Immunology and Microbiology, Laboratory of Nephrology and University Hospitals Leuven, Department of Nephrology and Renal Transplantation, B-3000 Leuven, Belgium
28 shared publications
Latest Publications
- Open Access
- 11 July 2023
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 16 (12) , 2578-2586
Leukopenia in autosomal dominant polycystic kidney disease: a single-center cohort of kidney transplant candidates with post-transplantation follow-up
Background: Autosomal dominant polycystic kidney disease (ADPKD) has occasionally been associated with lower peripheral white blood cell (WBC) counts. This study aimed to investigate the peripheral blood cell counts in a large cohort of kidney transplant recipients before and after kidney transplantation and its potential impact on post-transplant outcomes. Methods: This was a retrospective study with long-term follow-up data of 2090 patients who underwent a first kidney transplantation in the Leuven University Hospitals, of whom 392 had ADPKD. Results: In total, 2090 patients who underwent a first kidney transplantation in the Leuven University Hospitals were included, of whom 392 had ADPKD. Both pre- and post-transplantation, ADPKD patients had significantly lower total WBC counts, and more specifically lower neutrophil, lymphocyte and eosinophil counts compared with the non-ADPKD patients. This observation was independent of potential confounders such as level of inflammation, smoking habit, vitamins and pre-transplant medication. Overall survival and kidney transplant survival were significantly better in ADPKD vs non-ADPKD transplant recipients and a longer time to first infection was observed. However, no association between blood cell counts and outcome differences was found. Conclusions: In conclusion, this large single-center study reports a strong and independent association between ADPKD and lower peripheral WBC counts both before and after kidney transplantation. Considering the role of inflammation in disease progression, further investigation into the role of WBC in ADPKD is needed.
- 11 July 2023
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 16 (12) , 2578-2586
Open AccessLeukopenia in autosomal dominant polycystic kidney disease: a single-center cohort of kidney transplant candidates with post-transplantation follow-up
Background: Autosomal dominant polycystic kidney disease (ADPKD) has occasionally been associated with lower peripheral white blood cell (WBC) counts. This study aimed to investigate the peripheral blood cell counts in a large cohort of kidney transplant recipients before and after kidney transplantation and its potential impact on post-transplant outcomes. Methods: This was a retrospective study with long-term follow-up data of 2090 patients who underwent a first kidney transplantation in the Leuven University Hospitals, of whom 392 had ADPKD. Results: In total, 2090 patients who underwent a first kidney transplantation in the Leuven University Hospitals were included, of whom 392 had ADPKD. Both pre- and post-transplantation, ADPKD patients had significantly lower total WBC counts, and more specifically lower neutrophil, lymphocyte and eosinophil counts compared with the non-ADPKD patients. This observation was independent of potential confounders such as level of inflammation, smoking habit, vitamins and pre-transplant medication. Overall survival and kidney transplant survival were significantly better in ADPKD vs non-ADPKD transplant recipients and a longer time to first infection was observed. However, no association between blood cell counts and outcome differences was found. Conclusions: In conclusion, this large single-center study reports a strong and independent association between ADPKD and lower peripheral WBC counts both before and after kidney transplantation. Considering the role of inflammation in disease progression, further investigation into the role of WBC in ADPKD is needed.
- 23 June 2021
- Published by Universa BV in Tijdschrift voor Geneeskunde
Thuisdialyse bij ouderen: economische, ethische en medische reflecties
Home dialysis among elderly patients: economic, ethical and medical reflections It is a fact that the population in society is aging which is reflected in an increase in the number of patients with chronic renal disease and end-stage renal failure. As a logical consequence well-considered choices must be made regarding renal replacement therapy. Quality of life is an important factor and has to be taken into account when a specific choice is made regarding renal replacement therapy. Home dialysis among elderly patients should be considered a good option, taking into account the economic, medical, psychosocial and ethical challenges.
- 23 June 2021
- Published by Universa BV in Tijdschrift voor Geneeskunde
Thuisdialyse bij ouderen: economische, ethische en medische reflecties
Home dialysis among elderly patients: economic, ethical and medical reflections It is a fact that the population in society is aging which is reflected in an increase in the number of patients with chronic renal disease and end-stage renal failure. As a logical consequence well-considered choices must be made regarding renal replacement therapy. Quality of life is an important factor and has to be taken into account when a specific choice is made regarding renal replacement therapy. Home dialysis among elderly patients should be considered a good option, taking into account the economic, medical, psychosocial and ethical challenges.
- Open Access
- 28 November 2020
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 14 (8) , 1901-1907
Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study
In haemodialysis, maintaining patency of the extracorporeal circuit requires the use of anticoagulants. Although (low molecular weight) heparins are the mainstay, these are not well tolerated in all patients. Alternative approaches include saline infusion, citrate-containing dialysate, regional citrate anticoagulation or the use of heparin-coated membranes. Asymmetric cellulose triacetate (ATA) dialysers have a low degree of platelet contact activation and might be an alternative to heparin-coated dialysers. The aim of this study was to test the clotting propensity of ATA when used without systemic anticoagulation. We performed a Phase II pilot study in maintenance dialysis patients. The ‘Strategies for Asymmetrical Triacetate dialyzer heparin-Free Effective hemodialysis’ (SAFE) study was a two-arm open-label crossover study. In Arm A, patients were dialysed using 1.9 m2 ATA membranes in combination with a citrate-containing dialysate (1 mM). In Arm B, the ATA membrane was combined with high-volume predilution haemodiafiltration (HDF) without any other anticoagulation. The primary endpoint was the success rate to complete 4 h of haemodialysis without preterm clotting. Secondary endpoints included time to clotting and measures of dialysis adequacy. We scheduled 240 dialysis sessions (120/arm) in 20 patients. Patients were randomized 1:1 to start with Arm A or B. All patients crossed to the other arm halfway through the study. A total of 232 (96.7%) study treatments were delivered. Overall, 23 clotting events occurred, 7 in Arm A and 16 in Arm B. The success rate in Arm A (ATA + citrate-containing dialysate) was 90.8/94.0% [intention to treat (ITT)/as treated]. The success rate in Arm B (ATA + predilution HDF) was 83.3/86.2% (ITT/as treated). Time to clotting was borderline significantly better in Arm A (Mantel-Cox log rank P = 0.05). ATA dialysers have a low clotting propensity and both predilution HDF and a citrate-containing dialysate resulted in high rates of completed dialysis sessions.
- 28 November 2020
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 14 (8) , 1901-1907
Open AccessStrategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study
In haemodialysis, maintaining patency of the extracorporeal circuit requires the use of anticoagulants. Although (low molecular weight) heparins are the mainstay, these are not well tolerated in all patients. Alternative approaches include saline infusion, citrate-containing dialysate, regional citrate anticoagulation or the use of heparin-coated membranes. Asymmetric cellulose triacetate (ATA) dialysers have a low degree of platelet contact activation and might be an alternative to heparin-coated dialysers. The aim of this study was to test the clotting propensity of ATA when used without systemic anticoagulation. We performed a Phase II pilot study in maintenance dialysis patients. The ‘Strategies for Asymmetrical Triacetate dialyzer heparin-Free Effective hemodialysis’ (SAFE) study was a two-arm open-label crossover study. In Arm A, patients were dialysed using 1.9 m2 ATA membranes in combination with a citrate-containing dialysate (1 mM). In Arm B, the ATA membrane was combined with high-volume predilution haemodiafiltration (HDF) without any other anticoagulation. The primary endpoint was the success rate to complete 4 h of haemodialysis without preterm clotting. Secondary endpoints included time to clotting and measures of dialysis adequacy. We scheduled 240 dialysis sessions (120/arm) in 20 patients. Patients were randomized 1:1 to start with Arm A or B. All patients crossed to the other arm halfway through the study. A total of 232 (96.7%) study treatments were delivered. Overall, 23 clotting events occurred, 7 in Arm A and 16 in Arm B. The success rate in Arm A (ATA + citrate-containing dialysate) was 90.8/94.0% [intention to treat (ITT)/as treated]. The success rate in Arm B (ATA + predilution HDF) was 83.3/86.2% (ITT/as treated). Time to clotting was borderline significantly better in Arm A (Mantel-Cox log rank P = 0.05). ATA dialysers have a low clotting propensity and both predilution HDF and a citrate-containing dialysate resulted in high rates of completed dialysis sessions.
- Open Access
Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug–Bug Interaction?
Gut microbial metabolism is not only an important source of uremic toxins but may also help to maintain the vitamin K stores of the host. We hypothesized that sevelamer therapy, a commonly used phosphate binder in patients with end-stage kidney disease (ESKD), associates with a disturbed gut microbial metabolism. Important representatives of gut-derived uremic toxins, including indoxyl sulfate (IndS), p-Cresyl sulfate (pCS), trimethylamine N-oxide (TMAO), phenylacetylglutamine (PAG) and non-phosphorylated, uncarboxylated matrix-Gla protein (dp-ucMGP; a marker of vitamin K status), were analyzed in blood samples from 423 patients (65% males, median age 54 years) with ESKD. Demographics and laboratory data were extracted from electronic files. Sevelamer users (n = 172, 41%) were characterized by higher phosphate, IndS, TMAO, PAG and dp-ucMGP levels compared to non-users. Sevelamer was significantly associated with increased IndS, PAG and dp-ucMGP levels, independent of age, sex, calcium-containing phosphate binder, cohort, phosphate, creatinine and dialysis vintage. High dp-ucMGP levels, reflecting vitamin K deficiency, were independently and positively associated with PAG and TMAO levels. Sevelamer therapy associates with an unfavorable gut microbial metabolism pattern. Although the observational design precludes causal inference, present findings implicate a disturbed microbial metabolism and vitamin K deficiency as potential trade-offs of sevelamer therapy.
Open AccessSevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug–Bug Interaction?
Gut microbial metabolism is not only an important source of uremic toxins but may also help to maintain the vitamin K stores of the host. We hypothesized that sevelamer therapy, a commonly used phosphate binder in patients with end-stage kidney disease (ESKD), associates with a disturbed gut microbial metabolism. Important representatives of gut-derived uremic toxins, including indoxyl sulfate (IndS), p-Cresyl sulfate (pCS), trimethylamine N-oxide (TMAO), phenylacetylglutamine (PAG) and non-phosphorylated, uncarboxylated matrix-Gla protein (dp-ucMGP; a marker of vitamin K status), were analyzed in blood samples from 423 patients (65% males, median age 54 years) with ESKD. Demographics and laboratory data were extracted from electronic files. Sevelamer users (n = 172, 41%) were characterized by higher phosphate, IndS, TMAO, PAG and dp-ucMGP levels compared to non-users. Sevelamer was significantly associated with increased IndS, PAG and dp-ucMGP levels, independent of age, sex, calcium-containing phosphate binder, cohort, phosphate, creatinine and dialysis vintage. High dp-ucMGP levels, reflecting vitamin K deficiency, were independently and positively associated with PAG and TMAO levels. Sevelamer therapy associates with an unfavorable gut microbial metabolism pattern. Although the observational design precludes causal inference, present findings implicate a disturbed microbial metabolism and vitamin K deficiency as potential trade-offs of sevelamer therapy.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i245-i246
FP604 BONE MINERAL DENSITY, BONE TURNOVER AND PREVALENT AND INCIDENT FRACTURES IN DE NOVO RENAL TRANSPLANT RECIPIENTS
INTRODUCTION AND AIMS: Renal transplant recipients are at increased risk of fractures. The present prospective observational study investigated whether areal bone mineral density (aBMD) at the time of transplantation, as assessed by dual energy x-ray absorptiometry (DXA), can discriminate fracture status and predict incident fragility fractures in de novo renal transplant recipients and whether bone turnover markers (BTMs) may increase its diagnostic accuracy.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i245-i246
FP604 BONE MINERAL DENSITY, BONE TURNOVER AND PREVALENT AND INCIDENT FRACTURES IN DE NOVO RENAL TRANSPLANT RECIPIENTS
INTRODUCTION AND AIMS: Renal transplant recipients are at increased risk of fractures. The present prospective observational study investigated whether areal bone mineral density (aBMD) at the time of transplantation, as assessed by dual energy x-ray absorptiometry (DXA), can discriminate fracture status and predict incident fragility fractures in de novo renal transplant recipients and whether bone turnover markers (BTMs) may increase its diagnostic accuracy.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i254
FP627POOR VITAMIN K STATUS ASSOCIATES WITH LOW AREAL BONE MINERAL DENSITY AND PREDICTS FRACTURES IN DE NOVO RENAL TRANSPLANT RECIPIENTS
INTRODUCTION AND AIMS: Vitamin K deficiency is prevalent among patients with end stage renal disease. A poor vitamin K status associates with accelerated vascular calcification. Preliminary data indicate that poor vitamin K status may compromise bone health as well and that increased inflammation may be in the causal pathway. We investigated the association between vitamin K status, inflammation, bone mineral density and incident clinical fractures in a cohort of patients with ESRD, referred for single kidney transplantation.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i254
FP627POOR VITAMIN K STATUS ASSOCIATES WITH LOW AREAL BONE MINERAL DENSITY AND PREDICTS FRACTURES IN DE NOVO RENAL TRANSPLANT RECIPIENTS
INTRODUCTION AND AIMS: Vitamin K deficiency is prevalent among patients with end stage renal disease. A poor vitamin K status associates with accelerated vascular calcification. Preliminary data indicate that poor vitamin K status may compromise bone health as well and that increased inflammation may be in the causal pathway. We investigated the association between vitamin K status, inflammation, bone mineral density and incident clinical fractures in a cohort of patients with ESRD, referred for single kidney transplantation.
- Open Access
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i286-i287
FP715REMODELING ACTIVTY IS THE MAIN DRIVER OF BONE MINERAL DENSITY CHANGES IN DE NOVO RENAL TRANSPLANT RECIPIENTS
INTRODUCTION AND AIMS: Corticosteroids included in immunosuppressive protocols are traditionally thought to be the major culprit of bone mineral density loss in renal transplant recipients. In recent decades, steroid minimization immunosuppression protocols rapidly gained popularity. The present study aimed to investigate bone mass changes and correlates in contemporaneous de novo renal transplant recipients.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i286-i287
Open AccessFP715REMODELING ACTIVTY IS THE MAIN DRIVER OF BONE MINERAL DENSITY CHANGES IN DE NOVO RENAL TRANSPLANT RECIPIENTS
INTRODUCTION AND AIMS: Corticosteroids included in immunosuppressive protocols are traditionally thought to be the major culprit of bone mineral density loss in renal transplant recipients. In recent decades, steroid minimization immunosuppression protocols rapidly gained popularity. The present study aimed to investigate bone mass changes and correlates in contemporaneous de novo renal transplant recipients.
- 6 January 2018
- Published by Springer Nature in Pediatric Nephrology
- Vol. 33 (5) , 827-835
3DUS as an alternative to MRI for measuring renal volume in children with autosomal dominant polycystic kidney disease
Total kidney volume, measured by magnetic resonance imaging (MRI), is a validated disease progression marker in adults with autosomal dominant polycystic kidney disease (ADPKD). However, in childhood, MRI is burdensome, explaining the need for alternatives.
- 6 January 2018
- Published by Springer Nature in Pediatric Nephrology
- Vol. 33 (5) , 827-835
3DUS as an alternative to MRI for measuring renal volume in children with autosomal dominant polycystic kidney disease
Total kidney volume, measured by magnetic resonance imaging (MRI), is a validated disease progression marker in adults with autosomal dominant polycystic kidney disease (ADPKD). However, in childhood, MRI is burdensome, explaining the need for alternatives.
- Open Access
- 29 September 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (9) , e0185779
Clinicians’ attitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney disease
Several ethical aspects in the management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) are still controversial, including family planning and testing for disease presence in at-risk individuals. We performed an online survey aiming to assess the opinion and current clinical practice of European pediatric and adult nephrologists, as well as geneticists. A total of 410 clinicians (53% male, mean (SD) age of 48 (10) years) responded, including 216 pediatric nephrologists, 151 adult nephrologists, and 43 clinical geneticists. While the 3 groups agreed to encourage clinical testing in asymptomatic ADPKD minors and adults, only geneticists would recommend genetic testing in asymptomatic at-risk adults (PPP<0.05) appeared to be less convinced. Our survey suggests that most clinicians support clinical testing of at-risk minors and adults in ADPKD families. However, there is no agreement for genetic testing in asymptomatic offspring and for family planning, including PGD. The present data highlight the need for a consensus among clinicians, to avoid that ADPKD families are being given conflicting information.
- 29 September 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (9) , e0185779
Open AccessClinicians’ attitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney disease
Several ethical aspects in the management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) are still controversial, including family planning and testing for disease presence in at-risk individuals. We performed an online survey aiming to assess the opinion and current clinical practice of European pediatric and adult nephrologists, as well as geneticists. A total of 410 clinicians (53% male, mean (SD) age of 48 (10) years) responded, including 216 pediatric nephrologists, 151 adult nephrologists, and 43 clinical geneticists. While the 3 groups agreed to encourage clinical testing in asymptomatic ADPKD minors and adults, only geneticists would recommend genetic testing in asymptomatic at-risk adults (PPP<0.05) appeared to be less convinced. Our survey suggests that most clinicians support clinical testing of at-risk minors and adults in ADPKD families. However, there is no agreement for genetic testing in asymptomatic offspring and for family planning, including PGD. The present data highlight the need for a consensus among clinicians, to avoid that ADPKD families are being given conflicting information.
- 1 October 2016
- Published by Wolters Kluwer Health in Transplantation
- Vol. 100 (10) , 2188-2193
Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism
Background Sclerostin is an osteocyte-secreted soluble antagonist of the Wnt/β-catenin signaling pathway requisite for osteoblast development and activity. The regulation of sclerostin expression in bone is complex. Parathyroid hormone (PTH) is recognized to be an important suppressor. Circulating sclerostin levels are 2- to 4-fold higher in patients with end-stage renal disease as compared with individuals with normal renal function. Methods We performed a longitudinal observational cohort study and case-control study in 50 de novo renal transplant recipients, 50 chronic kidney disease (CKD) patients (n = 50) matched for age, sex, and estimated glomerular filtration rate, and 23 renal transplant recipients referred for parathyroidectomy to define the impact of renal transplantation on circulating sclerostin levels and to clarify the role of persistent (tertiary) hyperparathyroidism. Results Sclerostin serum levels decreased by 61.2% (median) during the first 3 months after transplantation (1.24 vs 0.44 ng/mL, P < 0.0001) to increase thereafter toward levels observed in CKD counterparts (0.63 ng/ml). High PTH levels independently associated with low sclerostin levels, both at time of transplantation and at 1 year. Sclerostin levels significantly increased after parathyroidectomy (0.49 vs. 0.32 ng/ml, P < 0.0001). The time course of bone biomarkers after parathyroidectomy suggests that bone resorption normalizes earlier than bone formation. Conclusions Circulating sclerostin levels appear to show a biphasic pattern after renal transplantation with a rapid and profound decrease, followed by gradual increase towards levels observed in CKD counterparts. Our data support the notion that PTH is an important regulator of circulating sclerostin levels.
- 1 October 2016
- Published by Wolters Kluwer Health in Transplantation
- Vol. 100 (10) , 2188-2193
Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism
Background Sclerostin is an osteocyte-secreted soluble antagonist of the Wnt/β-catenin signaling pathway requisite for osteoblast development and activity. The regulation of sclerostin expression in bone is complex. Parathyroid hormone (PTH) is recognized to be an important suppressor. Circulating sclerostin levels are 2- to 4-fold higher in patients with end-stage renal disease as compared with individuals with normal renal function. Methods We performed a longitudinal observational cohort study and case-control study in 50 de novo renal transplant recipients, 50 chronic kidney disease (CKD) patients (n = 50) matched for age, sex, and estimated glomerular filtration rate, and 23 renal transplant recipients referred for parathyroidectomy to define the impact of renal transplantation on circulating sclerostin levels and to clarify the role of persistent (tertiary) hyperparathyroidism. Results Sclerostin serum levels decreased by 61.2% (median) during the first 3 months after transplantation (1.24 vs 0.44 ng/mL, P < 0.0001) to increase thereafter toward levels observed in CKD counterparts (0.63 ng/ml). High PTH levels independently associated with low sclerostin levels, both at time of transplantation and at 1 year. Sclerostin levels significantly increased after parathyroidectomy (0.49 vs. 0.32 ng/ml, P < 0.0001). The time course of bone biomarkers after parathyroidectomy suggests that bone resorption normalizes earlier than bone formation. Conclusions Circulating sclerostin levels appear to show a biphasic pattern after renal transplantation with a rapid and profound decrease, followed by gradual increase towards levels observed in CKD counterparts. Our data support the notion that PTH is an important regulator of circulating sclerostin levels.